Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

a study on Autosomal Dominant Polycystic Kidney Disease Kidney Disease

Summary

Eligibility
for people ages 12-65 (full criteria)
Location
at UCLA UCSF
Dates
study started
study ends around

Description

Summary

The purpose of this study is to estimate the prevalence, demographic, and clinical characteristics of PKD1/2 gene variant groups in the ADPKD population.

Official Title

A Study to Determine the Prevalence and Clinical Characteristics Associated With PKD1 Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Keywords

Autosomal Dominant Polycystic Kidney Disease (ADPKD), ADPKD, Autosomal Dominant Polycystic Kidney

Eligibility

You can join if…

Open to people ages 12-65

  • Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 30 milliliter per minute (mL/min)/1.73 m2
  • Willing and able to comply with scheduled visits and other study procedures
  • A pre-existing diagnosis of ADPKD as defined in the protocol

You CAN'T join if...

  • History of kidney disease other than ADPKD that in the opinion of the investigator would independently impact the natural history of ADPKD
  • History of solid organ or bone marrow transplantation or nephrectomy
  • Ongoing renal replacement therapy or planning to start renal replacement therapy less than or equal to (≤)12 months from the Genotyping Visit in Part A

Other protocol defined Inclusion/Exclusion criteria will apply.

Locations

  • UCLA Division of Nephrology accepting new patients
    Los Angeles 5368361 California 5332921 90095 United States
  • Helen Diller Medical Center at Parnassus Heights accepting new patients
    San Francisco 5391959 California 5332921 94143 United States
  • Kaiser Permanente - Los Angeles Medical Center accepting new patients
    Los Angeles 5368361 California 5332921 90027 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Vertex Pharmaceuticals Incorporated
ID
NCT06747572
Study Type
Observational
Participants
Expecting 400 study participants
Last Updated